198 related articles for article (PubMed ID: 36342776)
1. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients.
Ajrawat P; Yang Y; Wasilewski E; Leroux T; Ladha KS; Bhatia A; Singh M; Thaker S; Kapoor M; Furlan AD; Kotra LP; Clarke H
Cannabis Cannabinoid Res; 2024 Feb; 9(1):267-281. PubMed ID: 36342776
[No Abstract] [Full Text] [Related]
2. Characterization of cannabinoid plasma concentration, maternal health, and cytokine levels in a rat model of prenatal Cannabis smoke exposure.
Black T; Baccetto SL; Barnard IL; Finch E; McElroy DL; Austin-Scott FVL; Greba Q; Michel D; Zagzoog A; Howland JG; Laprairie RB
Sci Rep; 2023 Nov; 13(1):21070. PubMed ID: 38030657
[TBL] [Abstract][Full Text] [Related]
3. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Fernández N; Cappello MG; Quiroga PN
Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
5. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
6. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.
Baron EP; Lucas P; Eades J; Hogue O
J Headache Pain; 2018 May; 19(1):37. PubMed ID: 29797104
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive effects of minor cannabinoids, terpenes and flavonoids in Cannabis.
Rodriguez CEB; Ouyang L; Kandasamy R
Behav Pharmacol; 2022 Apr; 33(2&3):130-157. PubMed ID: 33709984
[TBL] [Abstract][Full Text] [Related]
8. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model.
Eeswara A; Pacheco-Spiewak A; Jergova S; Sagen J
PLoS One; 2023; 18(3):e0282920. PubMed ID: 36913400
[TBL] [Abstract][Full Text] [Related]
9. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Hammond D; Goodman S
Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
[No Abstract] [Full Text] [Related]
10. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure.
Lambros AM; Sagar KA; Dahlgren MK; Kosereisoglu D; El-Abboud C; Smith RT; Gruber SA
Sci Rep; 2023 Apr; 13(1):5869. PubMed ID: 37041309
[TBL] [Abstract][Full Text] [Related]
11. An Approach to Biomarker Discovery of Cannabis Use Utilizing Proteomic, Metabolomic, and Lipidomic Analyses.
Hinckley JD; Saba L; Raymond K; Bartels K; Klawitter J; Christians U; Hopfer C
Cannabis Cannabinoid Res; 2022 Feb; 7(1):65-77. PubMed ID: 33998853
[No Abstract] [Full Text] [Related]
12. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.
Sakal C; Lynskey M; Schlag AK; Nutt DJ
Psychopharmacology (Berl); 2022 May; 239(5):1147-1155. PubMed ID: 33970291
[TBL] [Abstract][Full Text] [Related]
13. The Anti-Inflammatory Effects of
Zaiachuk M; Suryavanshi SV; Pryimak N; Kovalchuk I; Kovalchuk O
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446655
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of CBD, Δ
Jaidee W; Siridechakorn I; Nessopa S; Wisuitiprot V; Chaiwangrach N; Ingkaninan K; Waranuch N
Cannabis Cannabinoid Res; 2022 Aug; 7(4):537-547. PubMed ID: 34096805
[No Abstract] [Full Text] [Related]
15. Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.
Gibson LP; Mueller RL; Winiger EA; Klawitter J; Sempio C; Williams S; Bryan AD; Bidwell LC; Hutchison KE
Cannabis Cannabinoid Res; 2024 Feb; 9(1):320-334. PubMed ID: 36378267
[No Abstract] [Full Text] [Related]
16. Chemical profiling of Cannabis varieties cultivated for medical purposes in southeastern Brazil.
Carvalho VM; de Almeida FG; de Macêdo Vieira AC; Rocha ED; Cabral LM; Strongin RM
Forensic Sci Int; 2022 Jun; 335():111309. PubMed ID: 35462181
[TBL] [Abstract][Full Text] [Related]
17. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
18. Potency trends of cannabis in Jamaica during the period of 2014 to 2020.
Lindsay CM; Bernard KK; Hammond AM; Beckford S; Abel WD; Brown PD; Young LE
Drug Test Anal; 2024 Feb; 16(2):174-186. PubMed ID: 37309060
[TBL] [Abstract][Full Text] [Related]
19. Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying THC, CBD and their metabolites in hair. Application to patients treated with medical cannabis.
Lo Faro AF; Venanzi B; Pilli G; Ripani U; Basile G; Pichini S; Busardò FP
J Pharm Biomed Anal; 2022 Aug; 217():114841. PubMed ID: 35636009
[TBL] [Abstract][Full Text] [Related]
20. Receptor-mediated effects of Δ
Preteroti MW; Traboulsi H; Greiss P; Lapohos O; Fonseca GJ; Eidelman DH; Baglole CJ
Immunol Cell Biol; 2023 Feb; 101(2):156-170. PubMed ID: 36510483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
